TY - JOUR
T1 - Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids
AU - Shih, Vanessa
AU - Banks, Erika
AU - Bonine, Nicole G.
AU - Harrington, Amanda
AU - Stafkey-Mailey, Dana
AU - Yue, Binglin
AU - Ye, Jiatao Michael
AU - Fuldeore, Rupali M.
AU - Gillard, Patrick
N1 - Publisher Copyright:
© 2019, © 2019 Allergan PLC. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/11/2
Y1 - 2019/11/2
N2 - Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p <.0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p <.05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.
AB - Objective: To perform a retrospective, matched-cohort, longitudinal evaluation of annual pre- and post-diagnosis costs incurred among women with uterine fibroids (UF) (cases) compared to controls without UF. Methods: Data were derived from the IBM Watson Health MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 18–64 years with ≥1 inpatient or outpatient medical claim with an initial UF diagnosis (index date) from 1 January 2010 to 31 December 2014 were included. Healthcare resource utilization (HCRU) data including pharmacy, outpatient and inpatient hospital claims were collected for 1 year pre-index and ≤5 years post-index. All-cause costs (adjusted to 2017 $US) were compared between cases and controls using multivariable regression models. Results: Analysis included 205,098 (Commercial) and 24,755 (Medicaid) case–control pairs. HCRU and total all-cause healthcare costs were higher for cases versus controls during the pre-index year and all years post-index. Total unadjusted mean all-cause costs were $1197 higher (p <.0001; Commercial) and $2813 higher (standardized difference 0.08; Medicaid) for cases during the pre-index year. Total adjusted mean all-cause costs in the first year post-index were $14,917 for cases versus $5717 for controls in the Commercial population, and $20,244 versus $10,544, respectively, in the Medicaid population. In Years 2–5 post-index, incremental mean adjusted total costs decreased, but remained significantly higher for cases versus controls at all time points in both populations (all p <.05). Conclusions: Costs were higher for women with UF compared to women without UF during the pre-index year and over 5 years post-index; differences were greatest in the first year post-index.
KW - Cost
KW - economic burden
KW - healthcare resource utilization
KW - leiomyomata
KW - uterine fibroids
UR - http://www.scopus.com/inward/record.url?scp=85071323623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071323623&partnerID=8YFLogxK
U2 - 10.1080/03007995.2019.1642186
DO - 10.1080/03007995.2019.1642186
M3 - Article
C2 - 31290716
AN - SCOPUS:85071323623
SN - 0300-7995
VL - 35
SP - 1925
EP - 1935
JO - Current medical research and opinion
JF - Current medical research and opinion
IS - 11
ER -